Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials

被引：1
|
作者：
Venkatachalam, Meena
Stenehjem, David D.
Pietri, Guilhem
Penrod, John R.
Korytowsky, Beata
机构：
[1] Parexel, Waltham, MA USA
[2] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：4
相关论文
共 50 条
  • [21] ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN
    Suarez Rodriguez, J.
    Venkatachalam, M.
    Shaw, J. W.
    Contente, M.
    Polanco Sanchez, C.
    VALUE IN HEALTH, 2019, 22 : S448 - S448
  • [22] Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057.
    Gralla, Richard J.
    Spigel, David R.
    Bennett, Bryan
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Dastani, Homa
    Orsini, Lucinda Strycker
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Estimated costs of grade 3-4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC) in the CheckMate 227 (CM-227) trial.
    Stenehjem, David D.
    Santi, Irene
    Gupte-Singh, Komal
    Penrod, John R.
    Venkatachalam, Meena
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [24] CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Wu, Y.
    Chang, J.
    Zhang, L.
    Tu, H.
    Wu, L.
    Feng, J.
    Lu, S.
    Zhou, C.
    Wang, J.
    Mok, T.
    Taylor, F.
    Mossman, B.
    Penrod, J.
    Lawrance, R.
    Blum, S.
    Wang, P. F.
    Cheng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1048
  • [25] Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057
    Reck, Martin
    Brahmer, Julie
    Bennett, Bryan
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Dastani, Homa
    Spigel, David R.
    Gralla, Richard J.
    EUROPEAN JOURNAL OF CANCER, 2018, 102 : 23 - 30
  • [26] Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
    Horn, L.
    Brahmer, J.
    Reck, M.
    Borghaei, H.
    Spigel, D. R.
    Steins, M.
    Ready, E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Burgio, M. A.
    Fayette, J.
    Gettinger, S. N.
    Harbison, C. T.
    Li, A.
    Finckenstein, F. G.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 125 - 125
  • [27] Adverse events related to nivolumab in non-small cell lung cancer (NSCLC): a retrospective observational study
    Sassier, M.
    Oulkhouir, Y.
    Gervais, R.
    Alexandre, J.
    Humbert, X.
    Coquerel, A.
    Fedrizzi, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 31 - 32
  • [28] Evaluation of disease-related symptoms in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (NIVO) or docetaxel (DOC)
    Gralla, R. J.
    Coon, C.
    Taylor, F.
    Penrod, J. R.
    DeRosa, M.
    Dastani, H.
    Orsini, L.
    Reck, M.
    Oncology Research and Treatment, 2015, 38 : 14 - +
  • [29] Impact of of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study
    Reck, Martin
    Taylor, Fiona
    Penrod, John R.
    DeRosa, Michael
    Morrissey, Laura
    Dastani, Homa
    Orsini, Lucinda
    Gralla, Richard J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 194 - 204
  • [30] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Tu, Haiyan
    Wu, Lin
    Feng, Jifeng
    Zhang, Yiping
    Luft, Alexander Valeriercich
    Zhou, Jianying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Baudelet, Christine
    Li, Zoe
    Chang, Jianhua
    CANCER RESEARCH, 2018, 78 (13)
12345